Trials / Active Not Recruiting
Active Not RecruitingNCT06480565
A Phase 1/2 Trial of ADI-270 in ccRCC
A Phase 1/2 Trial of ADI-270 (Engineered γδ Chimeric Receptor [CAR] Vδ1 T Cells Targeting CD70) in Adults With Relapsed or Refractory (R/R) Clear Cell Renal Cell Carcinoma (ccRCC)
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Adicet Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1/2 multicenter, open-label, dose escalation, and dose expansion study of ADI-270 - an Engineered gamma-delta Chimeric Receptor \[CAR\] Vδ1 T Cell product Targeting CD70 - in patients with R/R ccRCC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ADI-270 | Anti-CD70 CAR-T |
| DRUG | Fludarabine | Chemotherapy for Lymphodepeletion |
| DRUG | Cyclophosphamide | Chemotherapy for Lymphodepletion |
Timeline
- Start date
- 2024-12-12
- Primary completion
- 2026-06-01
- Completion
- 2027-06-01
- First posted
- 2024-06-28
- Last updated
- 2025-08-15
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06480565. Inclusion in this directory is not an endorsement.